NCT01769391

A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer

A Randomized, Multicenter, Open-Label, Phase 2 Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Paclitaxel-Carboplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 167 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate if necitumumab added to standard chemotherapy of paclitaxel and carboplatin is more effective to treat cancer than the standard chemotherapy of paclitaxel and carboplatin alone.

Conditions

• Squamous Non Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Necitumumab	Administered IV
DRUG	Paclitaxel	Administered IV
DRUG	Carboplatin	Administered IV

Timeline

• Start date: 2013-01-01
• Primary completion: 2015-04-01
• Completion: 2017-07-01
• First posted: 2013-01-16
• Last updated: 2019-09-20
• Results posted: 2016-05-05

Locations

51 sites across 6 countries: United States, Germany, Mexico, Poland, Russia, South Korea